ICCM — IceCure Medical Ltd.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1584371 · Israel
Last close
$2.27
Market Cap
$7.78M
52W High
$9.54
52W Low
$2.12
ADV30
133,690
Next earnings
2026-08-12
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 911,000 295,000 -4,247,000 -4,274,000 13,303,000 8,115,000 4,809,000
Dec 2025 1,279,000 600,000 -4,216,000 -4,246,000 13,888,000 8,897,000 4,837,000
Sep 2025 850,000 277,000 -3,836,000 -3,859,000 15,078,000 4,971,000 5,772,000
Jun 2025 525,000 131,000 -3,385,000 -3,364,000 10,589,000 5,383,000 7,698,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,806,000
Investing CF
$-82,000
Financing CF
$16,809,000
CapEx
$-81,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.60
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-124,710,000
Inventory
$2,646,000
Receivables
$1,363,000
ST Investments
$5,034,000
EBIT TTM
$-15,684,000
Pretax Income TTM
$-15,743,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,947,000
EBITDA
$-16,439,000
Free Cash Flow
$-9,538,000
Enterprise Value
$-3,617,082
Total Cash
$12,034,000
Total Debt
$90,000
Shares Out
3,426,715
Trailing EPS
$-6.78
Book Value
$3.47
ROE
-228.3%
ROA
-73.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 3,379,000 -15,094,000 -15,057,000 13,888,000 4,837,000 -14,574,000
Dec 2024 3,291,000 -15,696,000 -15,318,000 12,576,000 5,675,000 -12,563,000
Dec 2023 3,229,000 -15,576,000 -14,652,000 16,410,000 4,247,000 -12,550,000
Dec 2022 3,085,000 -16,739,000 -16,978,000 30,188,000 4,766,000 -14,292,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-3.31

Peers — same industry

TickerNameMarket CapLastDaily %
CODX Co-Diagnostics, Inc. $7.63M $1.22
INBS INTELLIGENT BIO SOLUTIONS INC. $7.55M $2.50
NVNO enVVeno Medical Corp $7.07M $10.35
NXL Nexalin Technology, Inc. $6.95M $0.32
OSRH OSR Health, Inc. $8.78M $0.25

News headlines (Yahoo Finance, 1h cache)

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
2026-08-24 11:50 · Yahoo
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...
2026-08-20 03:01 · Yahoo
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
2026-08-19 15:43 · Yahoo
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
2026-08-13 13:10 · Yahoo
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
2026-08-12 12:30 · Yahoo
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
2026-08-05 12:30 · Yahoo
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
2026-07-27 12:32 · Yahoo
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
2026-07-14 12:32 · Yahoo
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
2026-07-06 12:11 · Yahoo
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
2026-06-17 17:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.